Q-omics provides the consensus-scored TP53RK profile across patient tissues and cancer cell-line models. TP53RK expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TP53RK is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, TP53RK RNA expression shows 19,135 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where TP53RK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TP53RK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TP53RK survival associations across molecular data types. TP53RK RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TP53RK RNA expression–survival associations across cancer types. High TP53RK expression shows unfavorable associations in UVM, LIHC, UCEC, DLBC, PAAD and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for TP53RK RNA expression.
This table summarizes TP53RK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TP53RK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TP53RK shows higher tumor expression in COAD, LIHC, HNSC, READ, STAD and BRCA. The COAD box plot shows higher TP53RK RNA expression in tumor versus normal tissue (log2 FC = +1.254, t-test p < 0.001).
This table shows molecular features associated with TP53RK in patient tissues and cancer cell lines. In patient samples, TP53RK shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TP53RK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
